Fort Lauderdale, FL – April 22, 2019 – Goodwin Biotechnology, Inc. (“Goodwin”) announced that it has completed its largest ever round of financing with growth capital which will help fund its next stage of expansion. Goodwin is a full GMP, FDA-registered biopharmaceuticals Contract Development and Manufacturing Organization (CDMO) that offers a fully integrated Single Source Solution™ from Cell Line Development, Process Development including Bioconjugation, Scale-Up, cGMP Contract Manufacturing and Aseptic Fill/Finish of mammalian cell-culture derived life-saving monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs). The investment was made by Signet Healthcare Partners (“Signet”), a New York based growth equity firm specializing in healthcare investments.
Concurrently, Nikhil Puri and Jerry Liao, investors at Signet, will join the board of directors of Goodwin Biotechnology. The growth capital will be used to support Goodwin’s investments in doubling its space available for cGMP capacity as it readies for further expansion of its biopharmaceutical manufacturing, including support for commercial product manufacturing and developing various capabilities to better serve its growing customer base.
Goodwin’s Chief Executive Officer Karl Pinto said, “Since the early 1990s Goodwin has served its clients in bringing their products through the clinic with our unmatched service, flexibility and quality. We are now at a point where the opportunity to grow and support our clients transcends the clinic and takes them into commercial manufacturing. Our efficient size, experience and breadth of capabilities position us very strongly to serve in particular, cutting edge “new biologics” products requiring small-to-mid volumes, to progress from the clinic and into the market, often within today’s shortened and abbreviated clinical pathways. We thank our loyal clients, employees, advisors and investors for helping us get here, and we welcome the Signet team to the Goodwin family. My management team and I look forward to working with them to scale our business as our clients and the market demand us to, and ultimately help patients with some of the newest medical technologies being developed.”
Signet Healthcare Partners Managing Director Nikhil Puri said “Goodwin has established leading vertically integrated capabilities in process development and clinical manufacturing of complex large molecules, evidenced by projects consummated with more than 100 clients. A substantial portion of new drug development pipeline are biologically derived, and I believe Goodwin is well positioned to serve biotech and pharma companies developing such products. Signet is very pleased to be partnering with the Company at this important inflection point, and we look forward to close collaboration with Karl and his leadership team at Goodwin.”
Fairmount Partners LP served as financial advisor for Goodwin. Pepper Hamilton LLP acted as legal counsel for Goodwin and Sheppard, Mullin, Richter & Hampton LLP acted as legal counsel for Signet Healthcare Partners.
About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a uniquely qualified and flexible, US-based CDMO that offers a Single Source Solution™ for our clients from cell line development, exploratory proof-of-concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody Drug Conjugates (ADCs) for early- and late-stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients’ lives. With over 26 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan’s Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing! In addition, Goodwin Biotechnology was awarded “Best in Sector: Biopharmaceutical Contract Development & Manufacturing” at Acquisition International magazine’s 2015 Sector Performance Awards. Last year, Goodwin Biotechnology received Global Health & Pharma’s 2017 award for Best for BioProcess Development & cGMP Manufacturing and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing. In 2018, Goodwin Biotechnology was named Biologics cGMP Manufacturer of the Year 2018 by Global Health & Pharma News. Click here to view the press releases! Additional information may be found at http://www.GoodwinBio.com.
About Signet Healthcare Partners
Signet Healthcare Partners (“Signet”) is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm’s focus has primarily been on the pharmaceutical sector and medical technology companies. Signet maintains a disciplined, yet flexible investment approach. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet’s 18-year history, it has developed a strong reputation and track record of successful investments. Signet has raised four funds with total capital commitments of over $400 million and has invested in more than 45 companies. For more information, visit http://www.signethealthcarepartners.com.
About Fairmount Partners
Based in Philadelphia, Fairmount Partners is the leading investment bank worldwide for pharmaceutical, device and related services businesses. Fairmount provides merger and acquisitions advisory services, and assists companies to raise funding for acquisitions, growth and liquidity. Fairmount’s Pharmaceutical Services Group has assisted clients to complete 133 transactions in 20 countries in North and South America, Europe, Asia and Australia. Further information is available at www.fairmountpartners.com.
Contact: Neal McCarthy email@example.com